US And European Guidelines Will Expand Neuromuscular Monitoring Adoption Worldwide

AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
Published
09 Apr 25
Updated
24 Jul 25
AnalystConsensusTarget's Fair Value
SEK 12.80
47.2% undervalued intrinsic discount
24 Jul
SEK 6.76
Loading
1Y
-17.5%
7D
-4.1%

Author's Valuation

SEK 12.8

47.2% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Increased 20%

Shared on24 Apr 25
Fair value Decreased 26%

AnalystConsensusTarget has decreased revenue growth from 91.1% to 80.9%, decreased profit margin from 20.2% to 10.3% and increased future PE multiple from 27.9x to 54.0x.

Shared on17 Apr 25
Fair value Increased 30%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.